PE20121352A1 - Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3 - Google Patents

Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3

Info

Publication number
PE20121352A1
PE20121352A1 PE2012000600A PE2012000600A PE20121352A1 PE 20121352 A1 PE20121352 A1 PE 20121352A1 PE 2012000600 A PE2012000600 A PE 2012000600A PE 2012000600 A PE2012000600 A PE 2012000600A PE 20121352 A1 PE20121352 A1 PE 20121352A1
Authority
PE
Peru
Prior art keywords
alkyl
purin
pyridin
oxo
inhibitors
Prior art date
Application number
PE2012000600A
Other languages
English (en)
Inventor
Solana Jorge Salas
Soliva Robert Soliva
Escrich Sergio Rodriguez
Gonzales Maria Cristina Sicre
Rosales Carmen Almansa
Original Assignee
Palau Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palau Pharma Sa filed Critical Palau Pharma Sa
Publication of PE20121352A1 publication Critical patent/PE20121352A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/06—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 containing at least one condensed beta-lactam ring system, provided for by groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00, e.g. a penem or a cepham system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A COMPUESTOS HETEROCICLICOS DE FORMULA (I) O (II) DONDE A Y B SON CADA UNO C O N; W ES CH O N; R1 Y R2 SON CADA UNO H, ALQUILO(C1-C4), HIDROXIALQUILO(C1-C4), CN, ENTRE OTROS; R3 ES ALQUILO(C1-C4), R9-ALQUILO(C1-C4), ENTRE OTROS, EN DONDE R9 ES HALOGENO, CN, ENTRE OTROS; R4 ES H, ALQUILO(C1-C4), HALOALQUILO(C1-C4), ENTRE OTROS; R5 ES H, ALQUILO(C1-C4), ALCOXI(C1-C4)-ALQUILO(C1-C4), ENTRE OTROS; R6 ES H, ALQUILO(C1-C4), HIDROXIALQUILO(C1-C4), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (S)-3-(2-(5-CIANOPIRAZOL[1,5-a]PIRIDIN-3-IL)-8-OXO-7H-PURIN-9(8H)-IL)-N,N-DIMETILPIPERIDIN-1-SULFONAMIDA; 3-(9-(1-ACETILPIRROLIDIN-3-IL)-7-METIL-8-OXO-8,9-DIHIDRO-7H-PURIN-2-IL)PIRAZOLO[1,5-a]PIRIDIN-5-CARBONITRILO; ACIDO (2R)-2-[2-(5-CIANOPIRAZOLO[1,5-a]PIRIDIN-3-IL)-8-OXO-7,8-DIHIDRO-9H-PURIN-9-IL]PROPANOICO; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON IHNIBIDORES DE CINASA DE JANUS (JAK) SIENDO UTILES EN EL TRATAMIENTO DE ARTRITIS REUMATOIDE, PSORIASIS, ESCLEROSIS MULTIPLE
PE2012000600A 2009-10-29 2010-10-29 Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3 PE20121352A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09382233 2009-10-29
US29105109P 2009-12-30 2009-12-30
US32992710P 2010-04-30 2010-04-30

Publications (1)

Publication Number Publication Date
PE20121352A1 true PE20121352A1 (es) 2012-10-15

Family

ID=41571618

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000600A PE20121352A1 (es) 2009-10-29 2010-10-29 Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3

Country Status (22)

Country Link
US (2) US8501735B2 (es)
EP (1) EP2493895B1 (es)
JP (1) JP5759471B2 (es)
KR (1) KR101675614B1 (es)
CN (1) CN102712658B (es)
AR (1) AR078833A1 (es)
AU (1) AU2010311378B2 (es)
BR (1) BR112012010186B8 (es)
CA (1) CA2778680C (es)
DK (1) DK2493895T3 (es)
ES (1) ES2629006T3 (es)
IL (1) IL219385A0 (es)
MX (1) MX2012005100A (es)
PE (1) PE20121352A1 (es)
PL (1) PL2493895T3 (es)
PT (1) PT2493895T (es)
RU (1) RU2553681C2 (es)
SI (1) SI2493895T1 (es)
TW (1) TWI478714B (es)
UA (1) UA109775C2 (es)
WO (1) WO2011051452A1 (es)
ZA (1) ZA201203090B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
EP2397482A1 (en) * 2010-06-15 2011-12-21 Almirall, S.A. Heteroaryl imidazolone derivatives as jak inhibitors
WO2012003576A1 (en) * 2010-07-06 2012-01-12 Université de Montréal Imidazopyridine, imidazopyrimidine and imidazopyrazine derivatives as melanocortin-4 receptor modulators
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
CA2825098C (en) 2011-01-27 2020-03-10 Universite De Montreal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
WO2013025628A1 (en) * 2011-08-15 2013-02-21 Ligand Pharmaceuticals Incorporated Janus kinase inhibitor compounds and methods
CN104053661B (zh) 2011-11-23 2018-06-19 癌症研究技术有限公司 非典型性蛋白激酶c的噻吩并嘧啶类抑制剂
WO2013117649A1 (en) * 2012-02-10 2013-08-15 Galapagos Nv Imidazo [4, 5 -c] pyridine derivatives useful for the treatment of degenerative and inflammatory diseases
UY34615A (es) * 2012-02-10 2013-09-30 Galapagos Nv Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias.
TW201513861A (zh) * 2013-01-17 2015-04-16 Galapagos Nv 用於治療退化性及發炎疾病之新穎化合物
US9650376B2 (en) 2013-03-15 2017-05-16 Knopp Biosciences Llc Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators
TWI663159B (zh) 2013-12-10 2019-06-21 美商健臻公司 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑
KR102409739B1 (ko) 2014-03-20 2022-06-17 카펠라 테라퓨틱스, 인크. 암 치료용의 ｅｒｂｂ 티로신 키나제 억제제로서의 벤즈이미다졸 유도체
ES2960991T3 (es) 2014-09-12 2024-03-07 Biohaven Therapeutics Ltd Benzoimidazol-1,2-ilamidas como activadores del canal Kv7
TWI780438B (zh) 2014-12-18 2022-10-11 美商健臻公司 原肌球蛋白相關激酶（ｔｒｋ）抑制劑之醫藥調配物
EP3053927A1 (en) 2015-02-05 2016-08-10 Vectura Limited Novel polymorphs
US10155757B2 (en) 2015-03-10 2018-12-18 Vectura Limited Crystalline form of a JAK3 kinase inhibitor
RU2750151C2 (ru) 2015-11-20 2021-06-22 Форма Терапьютикс, Инк. Гипоксантины в качестве ингибиторов убиквитин-специфической протеазы 1
ES2946551T3 (es) 2017-10-17 2023-07-20 Palau Pharma S L U Síntesis de compuestos de 4-aminopirimidina
TWI820146B (zh) * 2018-06-15 2023-11-01 瑞典商阿斯特捷利康公司 嘌呤酮化合物及其在治療癌症中之用途
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
US20220372135A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
CA3177830A1 (en) 2020-05-13 2021-11-18 Maria BECONI Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
CN112724133B (zh) * 2021-01-12 2022-03-25 湖南复瑞生物医药技术有限责任公司 6-溴吡唑并[1,5-a]吡啶的制备方法
WO2023248010A2 (en) 2022-06-23 2023-12-28 Synovo Gmbh Targeted modulators of jak3 for treatment of inflammatory and autoimmune diseases
EP4626403A2 (en) * 2022-12-02 2025-10-08 Kinaset Therapeutics, Inc. Formulation of a pan-jak inhibitor
WO2026030543A1 (en) 2024-07-31 2026-02-05 Kinaset Therapeutics, Inc. Treatment of copd patient populations

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
AU2003278088A1 (en) 2002-10-28 2004-05-25 Bayer Healthcare Ag Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors
EP1505064A1 (en) 2003-08-05 2005-02-09 Bayer HealthCare AG 2-Aminopyrimidine derivatives
TW200618800A (en) * 2004-08-03 2006-06-16 Uriach Y Compania S A J Heterocyclic compounds
AU2005278292B2 (en) * 2004-08-31 2011-09-08 Msd K.K. Novel substituted imidazole derivatives
WO2006053109A1 (en) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Heteroaryl compounds
KR20080013886A (ko) 2005-04-05 2008-02-13 파마코페이아, 인코포레이티드 면역억제용 퓨린 및 이미다조피리딘 유도체
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
WO2006110763A1 (en) 2005-04-08 2006-10-19 Bayer Pharmaceuticals Corporation Pyrimidine derivatives and their use for the treatment of cancer
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
EP2532667A1 (en) * 2005-09-30 2012-12-12 Vertex Pharmaceuticals Incorporated Deazapurines useful as inhibitors of janus kinases
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
AR063141A1 (es) * 2006-10-04 2008-12-30 Pharmacopeia Inc Derivados de 2- ( benzimidazolil ) purina 8- sustituida para inmunosupresion
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
TW200831104A (en) * 2006-10-04 2008-08-01 Pharmacopeia Inc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
NZ576278A (en) 2006-10-19 2011-12-22 Signal Pharm Llc Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
CA2669686A1 (en) 2006-11-16 2008-05-22 Pharmacopeia, Llc 7-substituted purine derivatives for immunosuppression
US20080119496A1 (en) * 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
WO2008119792A1 (en) * 2007-04-02 2008-10-09 Palau Pharma, S. A. Pyrrolopyrimidine derivatives as jak3 inhibitors
WO2008143674A1 (en) 2007-05-23 2008-11-27 Pharmacopeia, Inc. Purinones and 1h-imidazopyridinones as pkc-theta inhibitors
US8648069B2 (en) * 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
WO2009048474A1 (en) 2007-10-12 2009-04-16 Pharmacopeia, Inc. 2,7,9-substituted purinone derivatives for immunosuppression
PE20091035A1 (es) 2007-11-30 2009-07-16 Palau Pharma Sa Derivados de 2-aminopirimidina
WO2009077608A1 (en) 2007-12-19 2009-06-25 Palau Pharma, S. A. 2 -aminopyrimidine derivatives as histamine h4 antagonists
RU2489430C2 (ru) 2007-12-21 2013-08-10 Палау Фарма, С.А. Производные 4-аминопиримидина
GB0815369D0 (en) 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
EP2516420B8 (en) 2009-12-23 2018-10-17 Medicis Pharmaceutical Corporation Aminoalkylpyrimidine derivatives as histamine h4 receptor antagonists
JP2011136925A (ja) * 2009-12-28 2011-07-14 Dainippon Sumitomo Pharma Co Ltd 含窒素二環性化合物

Also Published As

Publication number Publication date
KR20120101402A (ko) 2012-09-13
AU2010311378B2 (en) 2014-04-24
PL2493895T3 (pl) 2017-10-31
ZA201203090B (en) 2013-09-25
RU2012122020A (ru) 2013-12-10
SI2493895T1 (sl) 2017-10-30
US20130289015A1 (en) 2013-10-31
DK2493895T3 (en) 2017-08-14
EP2493895B1 (en) 2017-04-26
RU2553681C2 (ru) 2015-06-20
PT2493895T (pt) 2017-07-05
TW201127385A (en) 2011-08-16
CN102712658B (zh) 2015-06-03
US8501735B2 (en) 2013-08-06
ES2629006T3 (es) 2017-08-07
CA2778680C (en) 2016-12-13
AR078833A1 (es) 2011-12-07
CA2778680A1 (en) 2011-05-05
BR112012010186B8 (pt) 2021-05-25
TWI478714B (zh) 2015-04-01
AU2010311378A1 (en) 2012-05-24
US20130131038A9 (en) 2013-05-23
BR112012010186B1 (pt) 2020-11-03
UA109775C2 (xx) 2015-10-12
US8946257B2 (en) 2015-02-03
HK1172327A1 (en) 2013-04-19
EP2493895A1 (en) 2012-09-05
WO2011051452A1 (en) 2011-05-05
CN102712658A (zh) 2012-10-03
IL219385A0 (en) 2012-06-28
BR112012010186A2 (pt) 2016-04-19
JP2013509382A (ja) 2013-03-14
US20120245140A1 (en) 2012-09-27
MX2012005100A (es) 2012-06-08
JP5759471B2 (ja) 2015-08-05
KR101675614B1 (ko) 2016-11-11

Similar Documents

Publication Publication Date Title
PE20121352A1 (es) Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3
PE20110545A1 (es) Compuestos de triazolopiridina como inhibidores de jak
PE20151249A1 (es) Derivados de pirazolopirimidina como inhibidores de jak quinasas
PE20141973A1 (es) Compuestos de heterociclilo como inhibidores de mek
PE20121438A1 (es) Derivados de imidazopiridina o imidazopirimidina como inhibidores de fosfodiesterasa 10a
PE20091623A1 (es) DERIVADOS DE 1H-PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE RAF QUINASA
PE20121482A1 (es) Derivados de imidazopiridina como inhibidores de jak
PE20050691A1 (es) Proceso para preparar carboxamidas 2-aminotiazol-5-aromaticas como inhibidores de la cinasa
PE20081888A1 (es) ANALOGOS DE PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE CINASA mTOR Y CINASA PI3
NZ629807A (en) Novel pyrrolopyrimidine compounds as inhibitors of protein kinases
PE20080659A1 (es) Benzotriazoles como moduladores de quinasas
MX2010004819A (es) Derivados de [1h-pirazolo[3,4-b]piridin-4-il]-fenilo o piridin-2-ilo como proteina cinasa c-theta.
CY1118969T1 (el) Ενωσεις πυριμιδινο-2-αμινης και η χρηση τους ως αναστολεις των κινασων jak
UY31126A1 (es) Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
PE20121529A1 (es) Compuestos derivados de piridopirimidina como inhibidores de pde4
PE20090210A1 (es) Compuestos derivados de pirazolo pirimidina como inhibidores de jak quinasa
PE20121327A1 (es) Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello
PE20061198A1 (es) Derivados de pirazol como inhibidores de cdk y gsk
PE20070593A1 (es) Compuestos pirrolopirimidina como inhibidores de syk
PE20130188A1 (es) Pirrolidinonas heteroaromaticas fusionadas como inhibidores de syk
AR077468A1 (es) Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
PE20121500A1 (es) 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2
NZ702571A (en) 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
EA201301319A1 (ru) Производные пиридин-2(1н)-она, применимые в качестве лекарственных средств для лечения миелопролиферативных нарушений, отторжения трансплантата, иммунологически обусловленных и воспалительных заболеваний
SG195085A1 (en) Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors

Legal Events

Date Code Title Description
FD Application declared void or lapsed